Systemic Metformin modulates acute systemic inflammation in non-diabetic periodontal patients
periodontitis, PD, diabetes
PERIODONTITIS, INFLAMMATION, POLYCYSTIC OVARIAN SYNDROME, ADVERSE EFFECTS, PATHOGENESIS, DIABETES
Systemic Metformin is widely used in the management of diabetes (and for non-diabetic treatments, such as Polycystic Ovarian Syndrome), however, it has never been used in periodontitis treatment management. Therefore, in order to investigate whether Metformin affects systemic-oral inflammation, an associated risk factor of the pathogenesis of PD [Since the recruited patients were non-diabetics, careful tracking of any adverse effects from the off-label use of Metformin for periodontal treatment was done. During the medication window, 4 participants reported adverse effects, two in each group (Additional file Periodontal treatment increases systemic inflammatory response in the first week post treatment [Acute systemic inflammatory reaction and diet during Metformin administration. The primary outcome of the trial was to determine any differences in acute phase elevations in levels of circulating C-reactive protein, assessed by high-sensitivity C-Reactive Protein assay (HsCRP) after treatment, and although no intergroup differences were seen, HsCRP levels were significantly elevated only in Placebo-treated patients in the intragroup analysis (+ 3.29 mg/dL; Since Metformin is a glucose metabolism modulatory drug, food consumption was investigated as a potential confounder in the analysis of systemic blood markers. Intergroup analysis of the diet diary collected from the participants showed that in general the participants had a similar diet and consumed a similar number of servings over the 10 days of medication (Additional file 